PMVP vs. PRPH, ABEO, ALLK, GNLX, DMAC, SLS, BTAI, ORMP, MIST, and BYSI
Should you be buying PMV Pharmaceuticals stock or one of its competitors? The main competitors of PMV Pharmaceuticals include ProPhase Labs (PRPH), Abeona Therapeutics (ABEO), Allakos (ALLK), Genelux (GNLX), DiaMedica Therapeutics (DMAC), SELLAS Life Sciences Group (SLS), BioXcel Therapeutics (BTAI), Oramed Pharmaceuticals (ORMP), Milestone Pharmaceuticals (MIST), and BeyondSpring (BYSI). These companies are all part of the "pharmaceutical preparations" industry.
ProPhase Labs (NASDAQ:PRPH) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, community ranking, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.
PMV Pharmaceuticals has a net margin of 0.00% compared to PMV Pharmaceuticals' net margin of -37.81%. PMV Pharmaceuticals' return on equity of -29.83% beat ProPhase Labs' return on equity.
ProPhase Labs presently has a consensus target price of $11.00, suggesting a potential upside of 133.55%. PMV Pharmaceuticals has a consensus target price of $5.67, suggesting a potential upside of 223.81%. Given ProPhase Labs' higher possible upside, analysts clearly believe PMV Pharmaceuticals is more favorable than ProPhase Labs.
ProPhase Labs received 97 more outperform votes than PMV Pharmaceuticals when rated by MarketBeat users. However, 54.84% of users gave PMV Pharmaceuticals an outperform vote while only 50.44% of users gave ProPhase Labs an outperform vote.
ProPhase Labs has a beta of -0.29, meaning that its stock price is 129% less volatile than the S&P 500. Comparatively, PMV Pharmaceuticals has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.
ProPhase Labs has higher revenue and earnings than PMV Pharmaceuticals. ProPhase Labs is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, ProPhase Labs had 12 more articles in the media than PMV Pharmaceuticals. MarketBeat recorded 12 mentions for ProPhase Labs and 0 mentions for PMV Pharmaceuticals. PMV Pharmaceuticals' average media sentiment score of 0.71 beat ProPhase Labs' score of 0.00 indicating that ProPhase Labs is being referred to more favorably in the media.
9.5% of ProPhase Labs shares are owned by institutional investors. Comparatively, 90.2% of PMV Pharmaceuticals shares are owned by institutional investors. 26.1% of ProPhase Labs shares are owned by insiders. Comparatively, 7.6% of PMV Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
ProPhase Labs beats PMV Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get PMV Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for PMVP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PMVP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
PMV Pharmaceuticals Competitors List
Related Companies and Tools
